会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • Methods for producing modified glycoproteins
    • 生产改性糖蛋白的方法
    • US20060148035A1
    • 2006-07-06
    • US11271235
    • 2005-11-10
    • Tillman Gerngross
    • Tillman Gerngross
    • C12P21/06C07H21/04C12N9/24C12N1/18C12N15/74
    • C12P21/005C07K2319/04C07K2319/05C12N1/14C12N9/1048C12N9/2488C12N15/79C12N15/80C12N15/81C12Y302/01C12Y302/01113
    • Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.
    • 已经开发了具有遗传修饰的糖基化途径的细胞系,其允许它们进行模拟人类中糖蛋白的加工的酶反应序列。 在这些工程化宿主中表达的重组蛋白可以产生与其对应物更相似的糖蛋白(如果基本上不相同)。 通常产生含有高甘露糖的N-聚糖(包括单细胞和多细胞真菌)的低等真核生物被修饰以产生N-聚糖,例如Man 3或GlcNAc 2 N或其它结构 沿着人类糖基化途径。 这是使用以下工程和/或选择的组合实现的:不表达产生真菌糖蛋白特征的不合需要的复合结构的某些酶,其表达选择在真菌中存在的条件下具有最佳活性的外源酶 其中需要活性或靶向实现最佳活性的细胞器,以及其组合,其中遗传工程真核生物表达产生“人样”糖蛋白所需的多种外源酶。
    • 10. 发明申请
    • Polyhydroxyalkanoates for In Vivo Applications
    • 聚羟基链烷酸酯用于体内应用
    • US20070280899A1
    • 2007-12-06
    • US11748723
    • 2007-05-15
    • Simon WilliamsDavid MartinTillman GerngrossDaniel Horowitz
    • Simon WilliamsDavid MartinTillman GerngrossDaniel Horowitz
    • A61K31/765
    • C12P7/625A61B17/06166A61B42/00A61K47/593A61K47/6957A61L15/26A61L17/10A61L27/18A61L27/34A61L29/06A61L31/06C08G63/06C08G63/6852C08G63/6882C08G63/912C12N5/0068C12N2533/30Y10S977/775Y10T428/139C08L67/04
    • Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.
    • 已经除去热原的聚羟基链烷酸酯(PHA)被提供用于许多生物医学应用。 已经化学改性以增强物理和/或化学性质的PHA用于通过网状内皮系统(RES)靶向或修饰生物降解性或清除的PHA。 还提供了通过细菌发酵方法制备的去氢原位PHA聚合物的方法,其中热原从聚合物中除去而不会不利地影响聚合物固有的化学结构和物理性质。 还描述了具有有利处理特性的PHA,包括低熔点和/或在无毒溶剂中的溶解度。 提供适用于体内应用的PHA,例如在组织包衣,支架,缝线,管,骨和其他假体,骨或组织水泥,组织再生装置,伤口敷料,药物递送以及诊断和预防用途中。 选择的性质包括降解性,弹性,包含官能团或衍生基团,其又可用于附着靶向剂,以及生物粘附。